Volume 93 Issue 19 | p. 7 | News of The Week
Issue Date: May 11, 2015

Inhibitors Make Rare Landing On Longstanding Anticancer Target Ras

Drug Discovery: Despite decades of effort, no Ras inhibitors have passed clinical trials, but cyclic peptides provide new options
Department: Science & Technology
News Channels: Biological SCENE
Keywords: Ras, inhibitors, cancer, cyclic peptides

Mutated Ras signaling proteins, frequently found in human cancer cells, are like airports with hard-to-find runways. They lack prominent binding sites for small molecules, so prospective anticancer drugs don’t land there very often. None has ever been approved commercially, despite decades of effort.

Dehua Pei, Roger Briesewitz, and coworkers at Ohio State University have now identified a group of cyclic peptides that inhibit several forms of human Ras (Angew. . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society